APA (7th ed.) Citation

Roth, P., Capper, D., Calabrese, E., Halasz, L. M., & Jakola, A. S. (2025). Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma. Neuro-Oncology Practice, 12, i29. https://doi.org/10.1093/nop/npae100

Chicago Style (17th ed.) Citation

Roth, Patrick, David Capper, Evan Calabrese, Lia M. Halasz, and Asgeir S. Jakola. "Role of the Tumor Board When Prescribing Mutant Isocitrate Dehydrogenase Inhibitors to Patients with Isocitrate Dehydrogenase-mutant Glioma." Neuro-Oncology Practice 12 (2025): i29. https://doi.org/10.1093/nop/npae100.

MLA (9th ed.) Citation

Roth, Patrick, et al. "Role of the Tumor Board When Prescribing Mutant Isocitrate Dehydrogenase Inhibitors to Patients with Isocitrate Dehydrogenase-mutant Glioma." Neuro-Oncology Practice, vol. 12, 2025, p. i29, https://doi.org/10.1093/nop/npae100.